Anne-Marie Koop

3 149 60. Enache I, Charles A-L, Bouitbir J, Favret F, Zoll J, Metzger D, Oswald-Mammosser M, Geny B, Charloux A. Skeletal muscle mitochondrial dysfunction precedes right ventricular impairment in experimental pulmonary hypertension. Mol Cell Biochem I. Enache, Service de Physiologie et d’Explorations Fonctionnelles, Pôle de Pathologie Thoracique, Centre Hospitalier Universitaire Strasbourg, Nouvel Hôpital Civil, 67091 Strasbourg, France; 2013;373:161–170. 61. Kojonazarov B, Luitel H, Sydykov A, Dahal BK, Paul-Clark MJ, Bonvini S, Reed A, Schermuly RT, Mitchell JA. The peroxisome proliferator-activated receptor beta/delta agonist GW0742 has direct protective effects on right heart hypertrophy. PulmCirc United States; 2013; 3 :926– 935. 62. Yoshinaga K, Ohira H, Tsujino I, Oyama-Manabe N, Mielniczuk L, Beanlands RSB, Katoh C, Kasai K, Manabe O, Sato T, Fujii S, Ito YM, Tomiyama Y, Nishimura M, Tamaki N. Attenuated right ventricular energetics evaluated using 11C-acetate PET in patients with pulmonary hypertension. Eur J Nucl Med Mol Imaging K. Yoshinaga, Department of Molecular Imaging, Hokkaido University, Graduate School of Medicine, Kita-Ku 060-8638m Sapporo Hokkaido, Japan; 2014;41:1240–1250. 63. Wang L, ZhangY, Yan C, He J, XiongC, Zhao S, FangW. Evaluation of right ventricularvolume and ejection fraction by gated 18F-FDG PET in patients with pulmonary hypertension: Comparison with cardiac MRI and CT. J Nucl Cardiol W. Fang, Department of Nuclear Medicine, Cardiovascular Institute, FuWai Hospital, Beijing 100037, China; 2013;20:242–252. 64. Lundgrin EL, Park MM, Sharp J, TangWHW, Thomas JD, Asosingh K, Comhair SA, DiFilippo FP, Neumann DR, Davis L, Graham BB, Tuder RM, Dostanic I, Erzurum SC. Fasting 2-deoxy- 2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc S.C. Erzurum, Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, United States; 2013;10:1–9. 65. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Fukumoto Y, Sakata Y, Shimokawa H. Crucial role of rho-kinase in pressure-overload-induced right ventricular hypertrophy and dysfunction in mice. J Card Fail S. Ikeda, Department of Cardiovascular Medicine, Tohoku University, Graduate School of Medicine, Sendai, Japan; 2014; 20 :S144. 66. Hemnes AR, Brittain EL, TrammellAW, Fessel JP, Austin ED, Penner N, Maynard KB, Gleaves L, Talati M, Absi T, Disalvo T, West J. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2014;189:325–334. 67. Rawat DK, Alzoubi A, Gupte R, Chettimada S, Watanabe M, Kahn AG, Okada T, McMurtry IF, Gupte SA. Increased reactive oxygen species, metabolic maladaptation, and autophagy contribute to pulmonary arterial hypertension-induced ventricular hypertrophy and diastolic heart failure. Hypertension S.A. Gupte, Department of Pharmacology, Center for Pulmonary Hypertension, BSB 546, New York Medical College, Valhalla, United States; 2014;64:1266–1274. 68. Liu B, Luo X-J, Yang Z-B, Zhang J-J, Li T-B, Zhang X-J, Ma Q-L, Zhang G-G, Hu C-P, Peng J. Inhibition of NOX/VPO1 pathway and inflammatory reaction by trimethoxystilbene in prevention of cardiovascular remodeling in hypoxia-induced pulmonary hypertensive rats. J Cardiovasc Pharmacol J. Peng, Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410078, China; 2014;63:567–576. 69. Ahmed LA, Obaid AAZ, Zaki HF, Agha AM. Naringenin adds to the protective effect of l-arginine in monocrotaline-induced pulmonary hypertension in rats: Favorable modulation